Skip to main content
Macrogen, Inc. logo

Macrogen, Inc. — Investor Relations & Filings

Ticker · 038290 ISIN · KR7038290003 KO Professional, scientific and technical activities
Open in API
Filings indexed 352 across all filing types
Latest filing 2024-11-26 Director's Dealing
Country KR South Korea
Listing KO 038290

About Macrogen, Inc.

https://www.macrogen.com/en/main

Macrogen, Inc. is a biotechnology company specializing in precision medicine and genomic analysis. It provides a comprehensive suite of services, including Next-Generation Sequencing (NGS), Sanger sequencing, and spatial transcriptome analysis, to a global client base. The company's core activities are focused on three key areas: Research and Data Analysis, offering fast and accurate genomic services to the scientific community; Clinical Diagnostics, advancing disease prediction through the integration of genomic and medical big data; and Personal Healthcare, providing genetic tests for wellness, nutrition, and disease risk assessment. By combining its extensive genomic expertise with big data and AI, Macrogen aims to deliver hyper-personalized healthcare solutions and innovate in the field of future medicine.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등거래계획보고서
Director's Dealing Classification · 100% confidence The document is an '임원ㆍ주요주주 특정증권등 거래계획보고서' (Report on Trading Plan for Specific Securities by Executives and Major Shareholders) filed by Macrogen. This document outlines a planned transaction (acquisition) of shares by a director/major shareholder (Seo Jeong Sun) for the purpose of securing management control. In the context of financial filings, reports detailing planned insider transactions or changes in shareholding structure by executives are classified as 'Director's Dealing' (DIRS) or 'Share Issue/Capital Change' (SHA). Given the specific nature of the 'Trading Plan' report under Korean regulatory requirements (often associated with insider trading disclosures), 'DIRS' is the most accurate classification for reporting personal share transactions or plans by directors.
2024-11-26 Korean
[기재정정]분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company Macrogen, Inc. (주)마크로젠, covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial statements (Income Statement, Statement of Changes in Equity), business descriptions, and management information. Although it is labeled as a '정정신고' (Correction Report) for a previously submitted quarterly report, it constitutes a comprehensive financial report for an interim period, fitting the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-22 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company Macrogen, Inc. (주)마크로젠, covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial information, business operations, management discussions, and capital structure, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
투자판단관련주요경영사항 (국가 통합 바이오 빅데이터 구축 사업 우선협상대상자 선정)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Macrogen) announcing that it has been selected as the preferred bidder for a government project ('National Integrated Bio-Big Data Construction Project'). It details the contract value, the nature of the project, and its significance relative to the company's revenue. Since this is a material corporate announcement regarding a business contract and does not fit into specific categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2024-10-28 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company Macrogen, covering the period from January 1, 2024, to June 30, 2024. It contains detailed financial information, business operations, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details a change in share ownership by a director (Kim Chang-hoon) of Macrogen. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2024-08-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.